Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$534M |
| 2 |
Amazon
AMZN
|
+$399M |
| 3 |
Abbott
ABT
|
+$381M |
| 4 |
Adobe
ADBE
|
+$353M |
| 5 |
Oracle
ORCL
|
+$261M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sherwin-Williams
SHW
|
+$407M |
| 2 |
Bank of America
BAC
|
+$368M |
| 3 |
TE Connectivity
TEL
|
+$366M |
| 4 |
Goldman Sachs
GS
|
+$302M |
| 5 |
Atlassian
TEAM
|
+$301M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.57% |
| 2 | Healthcare | 19.51% |
| 3 | Consumer Discretionary | 9.79% |
| 4 | Industrials | 9.79% |
| 5 | Financials | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Grab Holdings Warrant
GRABW
$569K
| $89.6K | ﹤0.01% |
403,754
| – | – |
|
2527
Coherus Oncology
CHRS
$227M
| $88.4K | ﹤0.01% |
26,496
+18
| +0.1% | +$48 |
|
2528
SES AI
SES
$200M
| $88K | ﹤0.01% |
47,948
+68
| +0.1% | +$147 |
|
2529
Erasca
ERAS
$6.48B
| $87K | ﹤0.01% |
40,739
-7
| -0% | -$15 |
|
2530
Microvast
MVST
$267M
| $84.7K | ﹤0.01% |
60,054
+67
| +0.1% | +$90 |
|
|
TE
2531
T1 Energy
TE
$1.19B
| $82.6K | ﹤0.01% |
44,046
-121
| -0.3% | -$326 |
|
|
FNCB
2532
DELISTED
FNCB Bancorp Inc. Common Stock
FNCB
| $81.6K | ﹤0.01% |
+12,013
| New | +$73.3K |
|
2533
Angi Inc
ANGI
$229M
| $74K | ﹤0.01% |
2,964
-8
| -0.3% | -$163 |
|
|
DM
2534
DELISTED
Desktop Metal, Inc.
DM
| $73.7K | ﹤0.01% |
9,813
-19
| -0.2% | -$172 |
|
|
VTYX
2535
DELISTED
Ventyx Biosciences
VTYX
| $44.7K | ﹤0.01% |
18,074
-1,688,710
| -99% | -$16M |
|
|
AGEN
2536
Agenus
AGEN
$329M
| $42.1K | ﹤0.01% |
2,541
-15
| -0.6% | -$249 |
|
2537
Traeger
COOK
$171M
| $33.4K | ﹤0.01% |
245
-1
| -0.4% | -$129 |
|
2538
Aclaris Therapeutics
ACRS
$743M
| $21.4K | ﹤0.01% |
20,300
-53
| -0.3% | -$162 |
|
|
EVA
2539
DELISTED
Enviva Inc.
EVA
| $14.7K | ﹤0.01% |
14,696
-59
| -0.4% | -$164 |
|
2540
Ambev
ABEV
$48.2B
| – | – |
-804,537
| Closed | -$2.07M |
|
2541
Aldeyra Therapeutics
ALDX
$96.5M
| – | – |
-25,239
| Closed | -$169K |
|
|
ALLK
2542
DELISTED
Allakos
ALLK
| – | – |
-33,566
| Closed | -$76.4K |
|
2543
American Well
AMWL
$181M
| – | – |
-4,583
| Closed | -$107K |
|
2544
Anika Therapeutics
ANIK
$240M
| – | – |
-304,556
| Closed | -$5.67M |
|
2545
AngioDynamics
ANGO
$610M
| – | – |
-17,193
| Closed | -$126K |
|
2546
Arcutis Biotherapeutics
ARQT
$3.5B
| – | – |
-22,724
| Closed | -$121K |
|
2547
AtaiBeckley Inc
ATAI
$2.66B
| – | – |
-61,391
| Closed | -$78.9K |
|
2548
American Vanguard Corp
AVD
$70.4M
| – | – |
-12,298
| Closed | -$134K |
|
2549
Axogen
AXGN
$2.2B
| – | – |
-20,561
| Closed | -$103K |
|
|
BCYC
2550
Bicycle Therapeutics
BCYC
$280M
| – | – |
-910,930
| Closed | -$18.3M |
|
Similar funds
Janus Henderson Group's Q4 2023 Portfolio in Review
As of Q4 2023, Janus Henderson Group held 2,657 positions worth $168B, up 9.8% from $153B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Janus Henderson Group's Q4 2023 filing shows 98 new, 642 increased, 1,760 reduced and 111 closed positions. Its largest new stake was Veralto: 2,881,576 shares worth $237M. The largest sale was Sherwin-Williams, an estimated $407M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q4 2023 buy was Veralto: 2,881,576 shares worth $237M.
- Janus Henderson Group added most to Eli Lilly in Q4 2023, an estimated $534M increase.
- Janus Henderson Group's biggest Q4 2023 reduction was Sherwin-Williams, cutting an estimated $407M.
- Janus Henderson Group fully exited National Instruments Corp in Q4 2023, selling an estimated $243M.
- Janus Henderson Group's ten largest holdings make up 27% of its $168B portfolio in Q4 2023.
- Janus Henderson Group opened 98 new positions and closed 111 in Q4 2023.
- Janus Henderson Group's portfolio value rose 9.8% quarter-over-quarter to $168B.
Based on Janus Henderson Group's 13F filing for Q4 2023, filed 14 Feb 2024.